APP-FUBINACA

APP-FUBINACA is an indazole-based synthetic cannabinoid that has been sold online as a designer drug.[1] Pharmacological testing showed APP-FUBINACA to have only moderate affinity for the CB1 receptor, with a Ki of 708 nM, while its EC50 was not tested.[2] It contains a phenylalanine amino acid residue in its structure.

APP-FUBINACA
Legal status
Legal status
Identifiers
IUPAC name
  • N-(1-amino-3-phenyl-1-oxopropan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC24H21FN4O2
Molar mass416.456 g·mol−1
3D model (JSmol)
SMILES
  • O=C(N[C@H](C(N)=O)CC1=CC=CC=C1)C2=NN(CC3=CC=C(F)C=C3)C4=C2C=CC=C4
InChI
  • InChI=1S/C24H21FN4O2/c25-18-12-10-17(11-13-18)15-29-21-9-5-4-8-19(21)22(28-29)24(31)27-20(23(26)30)14-16-6-2-1-3-7-16/h1-13,20H,14-15H2,(H2,26,30)(H,27,31)/t20-/m0/s1
  • Key:TZXBEYFALIFOAG-FQEVSTJZSA-N

Legality

Sweden's public health agency suggested to classify APP-FUBINACA as hazardous substance on March 24, 2015.[3]

See also

References

  1. "APP-FUBINACA". Cayman Chemical. Retrieved 15 July 2015.
  2. WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Hockerman SL, Jones DL, Kortum SW, Rico JG, Tenbrink RE, Wu KK, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc
  3. "Fler ämnen föreslås bli klassade som narkotika eller hälsofarlig vara". Folkhälsomyndigheten. Retrieved 16 July 2015.
  4. Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529. S2CID 227246346.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.